scholarly journals Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy

2009 ◽  
Vol 360 (1) ◽  
pp. 53-62 ◽  
Author(s):  
Robert S. Weinstein ◽  
Paula K. Roberson ◽  
Stavros C. Manolagas
Keyword(s):  
Osteoclast Formation ◽  
Bisphosphonate Therapy ◽  
Oral Bisphosphonate ◽  
Giant Osteoclast

Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy

Bone ◽  
2013 ◽  
Vol 56 (2) ◽  
pp. 426-431 ◽  
Author(s):  
Paola Franceschetti ◽  
Marta Bondanelli ◽  
Gaetano Caruso ◽  
Maria Rosaria Ambrosio ◽  
Vincenzo Lorusso ◽  
...  
Keyword(s):  
Risk Factors ◽  
Femoral Fractures ◽  
Bisphosphonate Therapy ◽  
Atypical Femoral Fractures ◽  
Oral Bisphosphonate

scholarly journals Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative

2017 ◽  
Vol 65 (9) ◽  
pp. 1924-1931 ◽  
Author(s):  
Rebecca L. Drieling ◽  
Andrea Z. LaCroix ◽  
Shirley A. A. Beresford ◽  
Denise M. Boudreau ◽  
Charles Kooperberg ◽  
...  
Keyword(s):  
Women’S Health ◽  
Women's Health ◽  
Older Women ◽  
Bisphosphonate Therapy ◽  
Women's Health Initiative ◽  
Women’S Health Initiative ◽  
Health Initiative ◽  
Oral Bisphosphonate ◽  
The Women’S Health Initiative

scholarly journals A Clinical and Histological Study about the Socket Preservation in a Patient under Oral Bisphosphonates Treatment: A Case Report

Biology ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 262
Author(s):  
Antonello Falco ◽  
Francesco Bataccia ◽  
Lorenzo Vittorini Orgeas ◽  
Federico Perfetti ◽  
Mariangela Basile ◽  
...  
Keyword(s):  
Case Report ◽  
Histological Study ◽  
Healing Process ◽  
Signs And Symptoms ◽  
Bisphosphonate Therapy ◽  
Graft Material ◽  
Oral Bisphosphonates ◽  
Socket Preservation ◽  
Oral Bisphosphonate ◽  
Histological Data

The aim of the present study is to assess the clinical and histological healing of a post-extractive alveolus following the procedure for socket preservation, in a patient receiving oral bisphosphonates for more than 6 years. After the extraction, enzymatically-deantigenated horse bone granules and an equine pericardium membrane were used to preserve the tooth socket. The patient was placed on a monthly follow-up in order to monitor the healing process. A 3 mm trephine bur was used to drill the bone for implant site preparation and to collect the bone sample. No signs and symptoms related to osteonecrosis of the jaws were reported. Histological data showed that, after 5 months, the mean percentages of trabecular bone, bone marrow and residual bone graft were respectively 45.74 ± 0.09%, 48.09 ± 0.08%, and 6.16 ± 0.01%. The residual graft material appeared to be osteointegrated and none of the particles appeared to be encapsulated. The present case report supports the guidelines that assume that patients undergoing oral bisphosphonate therapy can be eligible for surgical therapy. More clinical studies with larger sample sizes are needed to support this clinical evidence.

scholarly journals Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making

2021 ◽  
Vol 10 (5) ◽  
pp. 1140
Author(s):  
Kaleen N. Hayes ◽  
Elizabeth M. Winter ◽  
Suzanne M. Cadarette ◽  
Andrea M. Burden
Keyword(s):  
Surrogate Marker ◽  
Femoral Fractures ◽  
Osteonecrosis Of The Jaw ◽  
Bisphosphonate Therapy ◽  
Narrative Review ◽  
Drug Holiday ◽  
Future Research ◽  
Mineral Density ◽  
First Line Therapy

Bisphosphonates are first-line therapy for osteoporosis, with alendronate, risedronate, and zoledronate as the main treatments used globally. After one year of therapy, bisphosphonates are retained in bone for extended periods with extended anti-fracture effects after discontinuation. Due to this continued fracture protection and the potential for rare adverse events associated with long-term use (atypical femoral fractures and osteonecrosis of the jaw), a drug holiday of two to three years is recommended for most patients after long-term bisphosphonate therapy. The recommendation for a drug holiday up to three years is derived primarily from extensions of pivotal trials with alendronate and zoledronate and select surrogate marker studies. However, certain factors may modify the duration of bisphosphonate effects on a drug holiday and warrant consideration when determining an appropriate time off-therapy. In this narrative review, we recall what is currently known about drug holidays and discuss what we believe to be the primary considerations and areas for future research regarding drug holiday duration: total bisphosphonate exposure, type of bisphosphonate used, bone mineral density and falls risk, and patient sex and body weight.

Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy

2020 ◽  
Vol 30 (7) ◽  
pp. 599-610
Author(s):  
Cuixia Tian ◽  
Brenda L. Wong ◽  
Lindsey Hornung ◽  
Jane C. Khoury ◽  
Irina Rybalsky ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Glucocorticoid Therapy ◽  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate
Sign in / Sign up

Export Citation Format

Share Document